Get the Stockscreener App
3.05
2.56%
-0.08
After Hours:
3.12
0.07
+2.30%
Lantern Pharma Inc stock is traded at $3.05, with a volume of 37,662.
It is down -2.56% in the last 24 hours and down -12.61% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$3.13
Open:
$3.1
24h Volume:
37,662
Relative Volume:
0.86
Market Cap:
$32.91M
Revenue:
-
Net Income/Loss:
$-19.09M
P/E Ratio:
-1.7135
EPS:
-1.78
Net Cash Flow:
$-17.24M
1W Performance:
-7.29%
1M Performance:
-12.61%
6M Performance:
-4.98%
1Y Performance:
-51.59%
1-Day Range:
$2.97
$3.1472
1-Week Range:
$2.85
$3.27
52-Week Range:
$2.55
$6.40
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.05 | 35.48M | 0 | -19.09M | -17.24M | -1.78 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Here's Why We're Watching Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation - Yahoo Finance
Lantern pharma investors see $168,418 in stock sales By Investing.com - Investing.com Nigeria
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - Yahoo Finance
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials - BioSpace
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors at SNO Pediatric Conference - marketscreener.com
Lantern Pharma's LP-184 Shows Promise in Pediatric Brain Cancer | LTRN Stock News - GuruFocus
Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atyp - GuruFocus
Lantern Pharma’s LP-184 shows promise for pediatric brain cancer - Investing.com
FY2025 EPS Forecast for Lantern Pharma Increased by Analyst - Defense World
Zacks Small Cap Estimates Lantern Pharma Q2 Earnings - Defense World
Lantern Pharma outlines commercialization of radar AI modules and expects LP-184 trial enrollment completion by June 2025 - MSN
LTRN: First Quarter 2025 Financial Results - Yahoo Finance
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lake Street to Host Virtual Meeting Featuring LTRN on May 20 | L - GuruFocus
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance - Investing.com Nigeria
Lantern Pharma Advances AI-Driven Cancer Therapies - TipRanks
Lantern Pharma’s Earnings Call: Progress and Prospects - TipRanks
Lantern Pharma Q1 2025 slides: narrowing losses as clinical trials advance By Investing.com - Investing.com South Africa
Transcript : Lantern Pharma Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Lantern Pharma Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:LTRN) - Seeking Alpha
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss - Investing.com
Earnings call transcript: Lantern Pharma Q1 2025 reports narrower loss By Investing.com - Investing.com India
Lantern Pharma Q1 2025 Earnings Call Transcript - MarketBeat
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Reports Q1 2025 Financial Results - TipRanks
Lantern Pharma Inc. SEC 10-Q Report - TradingView
Yaber Highlights the Timeless Design and Natural Aesthetic of the T2 Series in "Lunar Rock" Colorway - Barchart.com
Why Beat Earnings When You Can Just Buy The Dip? - Barchart.com
BIG ROCK BREWERY INC. ANNOUNCES FIRST QUARTER 2025 RESULTS AND 51% INCREASE IN SALES VOLUMES - Barchart.com
The Ordre des arts et des lettres du Québec announces its 2025 cohortTen luminaries will become honorary members on June 9 - Barchart.com
Abigail Disney Urges Donors To Be Braver About Their Giving And Shouldering More Risk - Barchart.com
STATEMENTWith New Federal Health Minister Installed, It's Time To Get To Work: CMA - Barchart.com
Henry Mauriss Calls For A New Era Of Entrepreneurial Innovation In Media - Barchart.com
Phyllis Waud and Rebecca Murray of Syntax Named to CRN's 2025 Women of the Channel List - Barchart.com
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Tria - GuruFocus
What Is Moving The Markets Now? - Barchart.com
Trump sets 30-day deadline for pharmaceutical companies to lower US drug prices in executive order - Barchart.com
Tino’s Tree Service VA Prioritizes Property Protection with Fully Insured, Expert-Guided Tree Solutions - Barchart.com
Lantern Pharma (LTRN) Gets FDA Clearance for Clinical Trial Targeting Treatment-Resistant, Genomically-Defined Lung Cancer with AI developed LP-184 - Barchart.com
FDA clears LP-184 trial for NSCLC patients with specific mutations - Investing.com Nigeria
FDA Clears Lantern Pharma's (LTRN) Clinical Trial Amendment for NSCLC Treatment | LTRN Stock News - GuruFocus
Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need - NewsBreak: Local News & Alerts
FDA clears LP-184 trial for NSCLC patients with specific mutations By Investing.com - Investing.com South Africa
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients - Benzinga
The Conference Of Montreal 2025: Change, Vector Of Opportunities - Barchart.com
Google will pay $1.4 billion to Texas to settle claims the company collected data on users without permission - Barchart.com
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET - BioSpace
Lantern Pharma to Report First Quarter 2025 Operating & Financial Results on May 15th, 2025 at 9:00 a.m. ET | LTRN Stock News - GuruFocus
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):